The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Real world use of CAR T-cell therapy in multiple myeloma
Idecabtagene vicleucel (ide-cel) is a chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed/refractory multiple myeloma who have undergone 4 or more prior therapies. Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, comments on the number of patients who are able to receive ide-cel. Data from the Flatiron Health Electronic Health Record (EHR) suggests fewer than 15% of patients are eligible for treatment, with a number of patients dying before being eligible. Dr Costa thus highlights the need to approve CAR T-cell therapies for earlier lines of treatment. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
